Altered Behavior: An Infrequent Presentation with Levetiracetam

N. Patiyal, A. Bhardwaj, D. Kansal, A. Sood, Ankit Chauhan
{"title":"Altered Behavior: An Infrequent Presentation with Levetiracetam","authors":"N. Patiyal, A. Bhardwaj, D. Kansal, A. Sood, Ankit Chauhan","doi":"10.18231/J.JPBS.2020.013","DOIUrl":null,"url":null,"abstract":"Levetiracetam has been associated with aggressive behavior and mania.We are reporting a case of agitation and aggressive behavior following levetiracetam monotherapy for focal seizure prophylaxis. A 48 years old man, who presented to the neurology department with history of four episodes of sudden onset abnormal body movements. Patient was diagnosed with focal seizures with secondary generalization and was prescribed tablet levetiracetam 500 mg twice a day for seizure prophylaxis. Three weeks later patient presented with complaints of excessive sleepiness during daytime, agitation and aggressive behavior, though seizure free. According to World Health Organization Uppsala monitoring Centre (WHO-UMC) causality assessment system the case was classified as probable/likely for levetiracetam-induced altered behavior. Levetiracetam was discontinued, and tablet  carbamazepine controlled-release 300 mg twice daily was substituted. Within 2 days of switching therapy the agitation and aggression reduced substantially. Although levetiracetam has fewer side effects than traditional antiepileptic medications, but it is imperative to continuously monitor the patient for infrequent adverse effects also, so that required modifications to drug label may be done.\n\nKeywords: Aggression, Agitation, Altered behavior, Levetiracetam.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research journal of pharmaceutical, biological and chemical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/J.JPBS.2020.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Levetiracetam has been associated with aggressive behavior and mania.We are reporting a case of agitation and aggressive behavior following levetiracetam monotherapy for focal seizure prophylaxis. A 48 years old man, who presented to the neurology department with history of four episodes of sudden onset abnormal body movements. Patient was diagnosed with focal seizures with secondary generalization and was prescribed tablet levetiracetam 500 mg twice a day for seizure prophylaxis. Three weeks later patient presented with complaints of excessive sleepiness during daytime, agitation and aggressive behavior, though seizure free. According to World Health Organization Uppsala monitoring Centre (WHO-UMC) causality assessment system the case was classified as probable/likely for levetiracetam-induced altered behavior. Levetiracetam was discontinued, and tablet  carbamazepine controlled-release 300 mg twice daily was substituted. Within 2 days of switching therapy the agitation and aggression reduced substantially. Although levetiracetam has fewer side effects than traditional antiepileptic medications, but it is imperative to continuously monitor the patient for infrequent adverse effects also, so that required modifications to drug label may be done. Keywords: Aggression, Agitation, Altered behavior, Levetiracetam.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
行为改变:左乙拉西坦少见的表现
左乙拉西坦与攻击性行为和躁狂症有关。我们报告一例躁动和攻击行为后左乙拉西坦单药治疗局灶性癫痫发作预防。男,48岁,因4次突发性异常肢体运动病史就诊神经内科。患者诊断为局灶性癫痫发作,继发泛化,给予左乙拉西坦片剂500 mg,每日2次预防癫痫发作。三周后,患者出现白天嗜睡、躁动和攻击行为,但无癫痫发作。根据世界卫生组织乌普萨拉监测中心(世卫组织- umc)因果关系评估系统,该病例被归类为左乙拉西坦引起的行为改变的可能/可能。停用左乙拉西坦,改为卡马西平控释片300 mg,每日2次。在转换治疗的2天内,躁动和攻击明显减少。虽然左乙拉西坦的副作用比传统的抗癫痫药物要小,但也必须对患者进行持续监测,以防出现罕见的不良反应,以便对药物标签进行必要的修改。关键词:攻击,激越,行为改变,左乙拉西坦
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers Drug repurposing: A futuristic approach in drug discovery A review on ebola virus Evaluation and clinical management of drug-drug interactions in hypertensive patients associated co-morbidities: A study in general medicine and ICU ward Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1